Latest News
Navidea Biopharmaceuticals Names Farb-Horch and Winkler to Board of Directors
15 October 2021 - - US-based precision immunodiagnostic agents and immunotherapeutics company Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) has appointed Thomas Forest Farb-Horch and Agnieszka Winkler to its board of directors, each with a t...
FDA Approves Merck's Keytruda Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
15 October 2021 - - The US Food and Drug Administration has approved Keytruda, US-based pharmaceutical company Merck's (NYSE: MRK) anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients wi...
First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients with Advanced Solid Tumors
15 October 2021 - - The first patient has been dosed in US-based cancer immunotherapy company Immune-Onc Therapeutics, Inc's first-in-human clinical trial of IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunogl...
Amber Specialty Pharmacy Selected by ChemoCentryx to Dispense Tavneos, an Adjunctive Treatment for ANCA-Associated Vasculitis
15 October 2021 - - US-based Amber Specialty Pharmacy will begin dispensing Tavneos (avacopan), a first of its kind orally-administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-n...
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
15 October 2021 - - US-based life science company Agilent Technologies Inc's (NYSE: A) Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer at high risk of disease recurrence, f...